Business
Notice of Results, Analyst & Investor Presentation
N4 Pharma PLC will release its unaudited interim results for the six months ending June 30, 2025, on Thursday, September 25, 2025. An online analyst briefing, hosted by the Chief Executive Officer, will take place at 9:30 am on the same day to review these results. Following the briefing, an investor presentation covering the interim results will be held at 2:00 pm, open to existing and potential shareholders. Disclaimer*
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n \n \n \n19 September 2025\n \nN4 Pharma plc\n \n(\"N4 Pharma\" or the \"Company\")\n \nNotice of Results\nAnalyst Briefing and Investor Presentation\n \nN4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, will announce its unaudited interim results for the six months ended 30 June 2025 on Thursday, 25 September 2025 and hold the following analyst briefing and investor presentation.\n \nAnalyst briefing\n \nAn online briefing for analysts will be hosted by Nigel Theobald, Chief Executive Officer, at 9.30 am on Thursday, 25 September 2025, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at [email protected].\n \nInvestor presentation\n \nAn investor presentation to cover the interim results will be held at 2.00 pm on Thursday, 25 September 2025.\n \nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am on Wednesday, 24 September 2025 or at any time during the live presentation.\n \nInvestors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:\nhttps://www.investormeetcompany.com/n4-pharma-plc/register-investor\n \nInvestors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.\n \n- Ends -\nFor more information please contact:\n \n\n\n\n\nN4 Pharma plc\nNigel Theobald, CEO\nLuke Cairns, Executive Director\n \nSubmit your questions directly to the management team via the N4 Pharma Investor Hub\n\n\n \nVia N4 Pharma Investor Hub: investors.n4pharma.com\n \nhttps://n4pharma.com/link/y05doe\n\n\n\n\nSP Angel Corporate Finance LLP\nNominated Adviser and Joint Broker\nMatthew Johnson/Jen Clarke (Corporate Finance)\nVadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nTurner Pope Investments (TPI) Limited\nJoint Broker\nAndy Thacker\nJames Pope\n\n\nTel: +44 (0)20 3657 0050\n\n\n\n\nNorthstar Communications Limited\nInvestor Relations\nSarah Hollins\n\n\nTel: +44 (0)113 730 3896\n \n\n\n\n\n \nAbout...